IGF-1R Ligand Conjugates for Targeted Autoimmune Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Autoimmune diseases remain poorly understood and difficult to treat, contributing significantly to morbidity and mortality, with existing treatments often inadequate due to redundant signaling pathways and compensatory mechanisms.
Innovation Solution
Administering a conjugate comprising an IGF-1R ligand, such as insulin-like growth factor 1 (IGF-1) or variants, conjugated to a disease-modifying agent like a cytotoxic agent, specifically targeting and killing IGF-1R-expressing cells to alter their function or reduce their number, thereby bypassing redundant pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If simple IGF-1R pathway inhibition is used, then the treatment approach is simple, but redundant signaling pathways and compensatory mechanisms continue to act as disease effectors
Solution Approach 1:
The patent extracts and eliminates IGF-1R-expressing cells directly through conjugate-mediated cytotoxicity, rather than simply inhibiting the IGF-1R pathway. This extraction approach removes the source of redundant signaling and compensatory mechanisms that persist with simple pathway inhibition, thereby improving treatment reliability while maintaining conceptual simplicity.
Solution Approach 2:
The patent converts the harmful effect of IGF-1R expression (which drives autoimmune disease) into a beneficial targeting mechanism. By conjugating cytotoxic agents to IGF-1R ligands, the treatment uses the presence of IGF-1R-expressing cells as a guide to deliver destructive payloads specifically to these pathogenic cells, transforming a disease-promoting feature into a therapeutic advantage.
2Reliability
If IGF-1R-expressing cells are targeted and killed, then disease severity and progression are reduced, but hyperglycemia may occur
Solution Approach 1:
The patent applies local quality by delivering cytotoxic activity specifically to IGF-1R-expressing cells through conjugate-mediated targeting, rather than applying systemic cytotoxicity. The conjugate localizes the destructive effect to cells expressing the IGF-1R receptor, spares other cell types including pancreatic beta cells, and thus reduces disease severity while avoiding widespread hyperglycemia.
Solution Approach 2:
The IGF-1R ligand-conjugated cytotoxic agent acts as an intermediary that bridges the gap between treatment effectiveness and safety. The conjugate structure allows the cytotoxic payload to be delivered selectively through IGF-1R binding, serving as a mediator that achieves disease reduction without the broad systemic effects that would cause hyperglycemia.
3Ease of operation
If conventional autoimmune disease treatments are used, then disease symptoms are managed, but morbidity and mortality remain high
Solution Approach 1:
The patent extracts the root cause of autoimmune disease by targeting and eliminating IGF-1R-expressing cells, which are identified as the pathogenic driver. This extraction approach goes beyond symptom management to address the fundamental disease mechanism, thereby improving patient survival and health outcomes while maintaining treatment manageability through a clear therapeutic target.
Solution Approach 2:
The patent replaces conventional immunosuppressive mechanisms with a targeted cytolytic mechanism. Instead of broadly suppressing the immune system to manage symptoms, the treatment uses conjugate-mediated cytotoxicity to specifically eliminate the pathogenic IGF-1R-expressing cells, achieving superior clinical outcomes with potentially better safety profiles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment effectively modifies autoimmune diseases by reducing the number of IGF-1R-expressing cells, potentially offering a more comprehensive approach than simple IGF-1R inhibition, with the potential to reduce disease severity and progression without causing unacceptable hyperglycemia.
Implementation Method 1
The IGF-1R is a heterotetramer consisting of two extracellular ligand-binding a subunits and two transmembrane b subunits with kinase activity that mediate signal transduction
Implementation Method 2
the conjugate comprises an IGF-1R ligand, or portion or variant thereof, and a disease-modifying agent
Data Source
AI summary
The subject matter described herein provides methods for treating an autoimmune disease in a subject, comprising administering to the subject an effective amount of a conjugate that comprises an IGF-1R ligand, or portion or variant thereof, and a disease-modifying agent.